Clinical trials: Genotype 3
Chronic HCV Infection
Phase 3 Study of Yimitasvir Phosphate Capsules
The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection.
- Trial name
- NCT03487107
- Testing
- SOF, DAG181
- Where
- 35 sites in China
- Volunteers
- 362 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Chronic Hepatitis C Virus
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection
This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir fixed dose combination (FDC) with or without ribavirin (RBV) administered for 12 or 24 weeks in treatment-experienced subjects…
- Trial name
- ION-2 (NCT01768286)
- Testing
- LDV/SOF, RBV
- Where
- 53 sites in United States
- Volunteers
- 441 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
This randomized, parallel arm study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) in combination with 2 different doses of ribavirin in patients with chronic hepatitis C, genotype 2 or 3.
- Trial name
- NCT01258101
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin
- Where
- 18 sites in Austria
- Volunteers
- 395 people
- Sponsor
- Hoffmann-La Roche
Chronic HCV Infection
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir (SOF)+ ribavirin (RBV), with or without Pegylated interferon alfa (Peg-IFNα-2a/ PEG)) in participants with…
- Trial name
- NCT02021643
- Testing
- Sofosbuvir, RBV, PEG
- Where
- 35 sites in China, Hong Kong and 3 more
- Volunteers
- 687 people
- Sponsor
- Gilead Sciences
Inherited Ophthalmic Diseases, Hypopigmentation Disorder
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
Background: The eyeGENE (Registered Trademark) program is a research resource for inherited eye conditions which includes genotypic and phenotypic data, imaging, and a corresponding biobank of DNA samples from people with a…
- Conditions
- Inherited Ophthalmic Diseases, Hypopigmentation Disorder, Corneal Dystrophy, Blue-cone Monochromacy
- Trial name
- NCT06491615
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- National Eye Institute (NEI)
Hepatitis C, Genotype 1
Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
The purpose of this open label study is to evaluate the safety and efficacy of daclatasvir plus pegylated interferon-alfa 2a and ribavirin in untreated hepatitis C virus in patients coinfected with HIV
- Trial name
- NCT01471574
- Testing
- Daclatasvir, Ribavirin, PEG-Interferon alfa 2a
- Where
- 86 sites in United States, Argentina and 11 more
- Volunteers
- 549 people
- Sponsor
- Bristol-Myers Squibb
HCV
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.
The purpose of this study is to assess the efficacy and safety of Ravidasvir in combination with Danoprevir/r and ribavirin(RBV) by sustain virologic response 12 (SVR12), in treatment-naive, non-cirrhotic, chronic hepatitis C…
- Trial name
- NCT03362814
- Testing
- Ravidasvir, Danoprevir, Ritonavir
- Where
- China
- Volunteers
- 425 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Chronic Hepatitis C, Human Immunodeficiency Virus
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This is an Open-label Phase 3 study in adults with chronic genotypes 1, 2, 3, and 4 HCV infection who are co-infected with HIV-1.
- Trial name
- NCT01783678
- Testing
- Sofosbuvir, RBV
- Where
- 24 sites in Australia, France and 4 more
- Volunteers
- 275 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection
Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection
This study will have two parts as follows: The PK Lead-in Phase of the study will evaluate the steady state pharmacokinetics (PK) and confirm the dose of sofosbuvir (SOF) in hepatitis C virus (HCV)-infected pediatric…
- Trial name
- NCT02175758
- Testing
- SOF, RBV
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic Pain
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
The study is to investigate whether alisporivir (ALV; DEB025) alone or in combination with either ribavirin (RBV) or peginterferon alfa-2a (PEG) is more efficient compared to standard of care (PEG+RBV) in treatment-naïve…
- Trial name
- NCT01215643
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 340 people
- Sponsor
- Debiopharm International SA
Chronic Hepatitis C Infection
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil
The purpose of this study is to evaluate the proportion of subjects achieving sustained virologic response 12 weeks post-treatment (SVR12) in adults with genotype 1 (GT1) chronic HCV infection, who received treatment with 3…
- Trial name
- NCT02442271
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, ribavirin
- Volunteers
- 222 people
- Sponsor
- AbbVie
Healthy Subjects
A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers
To evaluate the pharmacokinetic (PK) profile of MIN-101 and its metabolites in extensive (EM) and poor (PM) metabolizers To evaluate the relationship between plasma levels of MIN-101 and changes in QT/QTcF intervals To evaluate…
- Trial name
- NCT03072056
- Testing
- MIN-101
- Where
- Ireland
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Minerva Neurosciences
Hepatitis C Virus Infection
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
The purpose of this study is to assess the anti-viral activity of BMS-790052 and BMS-650032 combination therapy in Japanese subject.
- Trial name
- NCT01718145
- Testing
- Daclatasvir, Asunaprevir, Ribavirin
- Where
- 48 sites in Japan
- Volunteers
- 258 people
- Sponsor
- Bristol-Myers Squibb
Complete and Accurate Statistical Data of 60 Patients, CYP3A5*3 Genotypes of 60 Donors and Recipients Were Analyzed Accurately
Analysis of the Effect of Donor CYP3A5 Gene Polymorphism on Early Tacrolimus Concentration and Postoperative Acute Renal Injury After Liver Transplantation
Tacrolimus is the most commonly used immunosuppressant for preventing and treating rejection after liver transplantation. However, its treatment window is narrow, the pharmacokinetic individual differences are large, routine dose…
- Conditions
- Complete and Accurate Statistical Data of 60 Patients, CYP3A5*3 Genotypes of 60 Donors and Recipients Were Analyzed Accurately, Postoperative Tacrolimus Concentrations Were Accurately Recorded in 60 Patients, According to the Diagnosis and Grading Criteria of Acute Kidney Injury, the Cases and Grading of Postoperative Acute Kidney Injury in 60 Patients Were Counted
- Trial name
- NCT06319391
- Testing
- CYP3A5*1*、CYP3A5*1*3, CYP3A5*3*3
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ziqiang Li
Hepatitis C
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
The purpose of this study is to determine whether a regimen consisting of daclatasvir and asunaprevir is effective in treatment-naive patients with chronic hepatitis genotype 1b infection.
- Trial name
- NCT02496078
- Testing
- Daclatasvir, Asunaprevir
- Where
- 29 sites in China, Russia and 1 more
- Volunteers
- 207 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants
The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in participants who are infected with genotype 1 hepatitis C virus who have never received treatment before.
- Trial name
- QUEST-2 (NCT01290679)
- Testing
- TMC435, Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Ribavirin (RBV)
- Where
- 60 sites in United States, Argentina and 13 more
- Volunteers
- 393 people
- Sponsor
- Janssen R&D Ireland
Hepatitis C
A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3
The purpose of this study is to determine if 8 weeks of Daclatasvir plus Sofosbuvir with or without Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients without advanced fibrosis or liver…
- Trial name
- NCT02551861
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 12 sites in Canada, France
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C, Co-Infection HIV-HCV
Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV
The rapidly progression of the disease in HIV-HCV co-infected patients justify the treatment. Combination of Peg interferon and Ribavirin is the best treatment because it improve the compliance of treatment.
- Trial name
- NCT00611819
- Testing
- Peg interferon + Ribavirin
- Where
- 18 sites in Spain
- Volunteers
- 59 people
- Sponsor
- University of Valencia
Chronic Hepatitis C
Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM
Peg interferon and ribavirin currently represent the standard approved association for treating patients infected with hepatitis C virus (HCV) .
- Trial name
- CINAM (NCT00199719)
- Testing
- Ribavirine
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Limoges
Hepatitis C Virus Infection
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks compared to treatment with sofosbuvir (SOF)…
- Trial name
- ASTRAL-2 (NCT02220998)
- Testing
- SOF/VEL, SOF, RBV
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 269 people
- Sponsor
- Gilead Sciences